1. Ide C. Peripheral nerve regeneration. Neurosci Res 1996; 25:101-121.
2. Karanth S, Yang G, Yeh J, Richardson PM. Nature of signals that initiate the immune response during Wallerian degeneration of peripheral nerves. Exp Neurol 2006; 202:161-166.
3. Nguyen MD, Julien JP, Rivest S. Innate immunity: the missing link in neuroprotection and neurodegeneration? Nat Rev Neurosci 2002; 3:216-227.
4. Tuszynski MH, Steward O. Concepts and methods for the study of axonal regeneration in the CNS. Neuron 2012; 74:777-791.
5. Steinman L. Elaborate interactions between the immune and nervous systems. Nat Immunol 2004; 5:575-581.
6. Profyris C, Cheema SS, Zang D, Azari MF, Boyle K, Petratos S. Degenerative and regenerative mechanisms governing spinal cord injury. Neurobiol Dis 2004; 15:415-436.
7. Camara-Lemarroy CR, Guzman-de la Garza FJ, Fernandez-Garza NE. Molecular inflammatory mediators in peripheral nerve degeneration and regeneration. Neuroimmunomodulation 2010; 17:314-324.
8. Ha GK, Parikh S, Huang Z, Petitto JM. Influence of injury severity on the rate and magnitude of the T lymphocyte and neuronal response to facial nerve axotomy. J Neuroimmunol 2008; 199:18-23.
9. Temporin K, Tanaka H, Kuroda Y, Okada K, Yachi K, Moritomo H, et al. Interleukin-1 beta promotes sensory nerve regeneration after sciatic nerve injury. Neurosci Lett 2008; 440:130-133.
10. Amadori A, Zamarchi R, De Silvestro G, Forza G, Cavatton G, Danieli GA, et al. Genetic control of the CD4/CD8 T-cell ratio in humans. Nat Med 1995; 1:1279-1283.
11. Shokouhi G, Tubbs RS, Shoja MM, Hadidchi S, Ghorbanihaghjo A, Roshangar L, et al. Neuroprotective effects of high-dose vs low dose melatonin after blunt sciatic nerve injury. Childs Nerv Syst 2008; 24:111–117.
12. Chlebicki CA, et al. The sciatic nerve transection in the third treatment group was performed by severing the left sciatic nerve with a scalpel. Lasers Surg Med 2010; 42:306–312.
13. Blackburn GL. Metabolic considerations in management of surgical patients. Surg Clin North Am 2011; 91:467-480.
14. Duarte-Rey C, Bogdanos DP, Leung PS, Anaya JM, Gershwin ME. IgM predominance in autoimmune disease: genetics and gender. Autoimmun Rev 2012; 11:A404-412.
15. Torgerson TR. Overview of routes of IgG administration. J Clin Immunol 2013; 33:S87-89.
16. Gaudet AD, Popovich PG, Ramer MS. Wallerian degeneration: gaining perspective on inflammatory events after peripheral nerve injury. J Neuroinflammation 2011; 8:110.
17. Tian P, et al. Orthop Surg 2009; 1, 4: 317–321.
18. Hendriks JJ, Teunissen CE, de Vries HE, Dijkstra CD. Macrophages and neurodegeneration. Brain Res Brain Res Rev 2005; 48:185-195.
19. Koeppen AH. Wallerian degeneration: history and clinical significance. J Neurol Sci 2004; 220:115-117.
20. Zochodne DW. The microenvironment of injured and regenerating peripheral nerves. Muscle Nerve Suppl 2000; 9:S33-38.